explore -WSS

explore

author：entertainment 2025-09-30 23:45:26 - browse：551

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The pain doctors face in trying to build their families

WSS

New definition of a human embryo proposed amid rapid advances

WATCH: Why do our ears pop?

WATCH: Why do our ears pop?

Researchers tackle phage therapy hurdles for wider adoption

Hilary expected to bring catastrophic, life

ProMED sees offers of support, but its future remains unclear

knowledge

explore

focus

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

The cancer drug shortage isn’t new — and neither are the solutions

New study raises questions about niacin and heart health

Apple is now the first public company to be valued at $3 trillion

Surprise medical billing ban raises prices elsewhere

Duchenne breakthrough therapy leaves behind pioneering families

MD Anderson's Padmanee Sharma responds to research credit suit

At least 13 dead in Texas as scorching temps continue

WATCH: Why do our ears pop?

hotspot

WATCH: Why do our ears pop?

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

New definition of a human embryo proposed amid rapid advances

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

An interview with Robert F. Kennedy Jr. on vaccines

FDA warns medical device makers about rise in fabricated data

leisure time

explore

Wikipedia

hotspot